Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @Amarincorp
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Amarincorp
-
Amarin has launched
#TrueToYourHeart – a campaign to educate people on how they can better protect themselves against persistent#cardiovascular risk. 1 in 3 American adults are living with some form of#CV disease. Learn more: https://bit.ly/2QPiN2Q pic.twitter.com/0g3wyeGdIS
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Wonderful start to 2020! AHA tout's Amarin's REDUCE-IT as one of the "Top Heart Disease and Stroke Research Advances in 2019." Second year in a row for REDUCE-IT. https://bit.ly/2QGNRjX .
#HeartHealth#cardiotwitter#AMRNHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
More good news for patients. Canada approves Vascepa. Congrats to our partner HLS Therapeutics, https://bit.ly/2ZKMZyH .
#hearthealth#cardiotwitter.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
New FDA approval of Amarin’s drug is first-ever approved for such indication. https://prn.to/2LQlaj2
#hearthealth#AMRNHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Proud to have our landmark study, REDUCE-IT®, recognized as one of the most important advances in preventative cardiology during the past decade! https://bit.ly/38qReDE
#hearthealth#CardioTwitter#AMRNHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amarin salutes
#AHA19 for continuing the dialogue on improving CV Health. We were proud to be part of the conversation.#hearthealth,#AMRNpic.twitter.com/FThmBgjua0
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
"The award
@EY_EOYUS is a tribute to the significant pioneering progress made by Amarin’s dedicated employees in advancing cost-effective preventative care solutions for reducing the risk of cardiovascular disease," says John Thero, President and CEO.#AMRN#EOYUSpic.twitter.com/RzrYa8YiQI
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
FDA’s Endocrinologic and Metabolic Drugs Advisory Committee recommends approval for expanded use of Amarin’s therapy. Read more here: https://bit.ly/379Q0Mj
#hearthealth#AMRN#EMDACHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Tune in, https://youtu.be/NZI3fV5gGL8 , as Dr. Bhatt leads a discussion on emerging treatment approaches for reducing cardiovascular risk.
#AHA#HeartHealth,#cardiotwitterHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The
@American_Heart estimates the cost of treating#CVD will exceed $1 trillion by 2035. Amarin CEO John Thero provides insight into how we can reverse this trend, save lives & reduce the tremendous burden on families & our economy: https://bit.ly/2KgMq9i#HearthealthHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amarin is proud to support the discussion on urgent challenges in cardiovascular disease.
#heartdisease#CardioTwitterhttps://twitter.com/AHANewJersey/status/1192557084296044545?s=20 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Amarin’s growth was again positive in Q3. We reported record revenue levels, positive cash flow and a strong financial position while adding to the breadth, depth and experience of our commercial organization. See Q3 press release, https://bit.ly/33pve9u .
$AMRNHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hello Philly! Amarin is back at the American Heart Association Scientific Sessions, https://bit.ly/2PH5ktL , 11/16-18 – sharing more data on icosapent ethyl (Vascepa®) and cardiovascular disease.
#AHA19,#cardiotwitter,#LateBreakingScienceHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Residual cardiovascular risk in patients on statins remains an important unmet medical issue. @NLA issued an important statement on addressing. Check out Amarin's press release https://bit.ly/2kmjenR .
#hearthealth,#AMRNHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
AMRN proslijedio/la je Tweet
IMPORTANT UPDATE:
#NLAFallCLU accredited program: The Evolving Landscape of Triglyceride Lowering and Cardiovascular Outcomes: Clinical Pearls and Patient Application, Friday, 9/13, 7-9 PM featuring Dr. Ann C. Skulas-Ray,@lipiddoc Dr. James Underberg, and Dr. Kevin C. Maki.pic.twitter.com/HTuideGnJp
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
AMARIN consolidates U.S. presence into new offices,
#Bridgewaternj, supporting further growth!pic.twitter.com/bJwqqQfPqK
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Check out Amarin’s press release on the new 2019 updates to the ECS/EAS updated clinical practice guidelines for dyslipidaemias. Read more here https://bit.ly/2k1nXv0
#ESCCongress#ESCGuidelines#HeartHealthpic.twitter.com/vxOJKHmG9k
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Strong interest in Medscape Live satellite symposium @
#ESCcongress2019 on treating CVD with omega-3 fatty acids (Bhatt, Weintraub, Mason).#hearthealthpic.twitter.com/FzXy7QlvLL
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our team is at
#ESCCongress2019 in Paris and looking forward to discussing global cardiovascular health with HCPs committed to#HeartHealthpic.twitter.com/0GBFdKXIJ9
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#DYK: there are new scientific guidelines about treating cardiovascular risks, including elevated triglycerides, diabetes, and LDL-cholesterol? https://bit.ly/2Cm304G#heart#hearthealth#ESCcongress2019Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.